Indivior Reports Record 2025 Results, Launches Share Buyback

An update from Indivior ( (INDV) ) is now available.

Indivior reported on February 26, 2026, that it delivered record fourth-quarter and full-year 2025 results driven by SUBLOCADE, with net revenue from the drug rising 13% for the year to $856 million and 30% in the quarter to $252 million, helping push full-year adjusted EBITDA up 20% to $428 million and GAAP net income to $210 million. The company completed Phase I of its Indivior Action Agenda, paid off a $295 million legacy DOJ obligation, relocated its corporate domicile from the U.K. to the U.S., entered Phase II focused on accelerating SUBLOCADE growth and cash generation, reaffirmed its 2026 guidance, and authorized a new $400 million share buyback program, underscoring stronger financial flexibility and an emphasis on shareholder returns.

The most recent analyst rating on (INDV) stock is a Hold with a $35.00 price target. To see the full list of analyst forecasts on Indivior stock, see the INDV Stock Forecast page.

Spark’s Take on INDV Stock

According to Spark, TipRanks’ AI Analyst, INDV is a Neutral.

The score is driven by a strong operational and cash-flow rebound plus constructive guidance/cost actions, but is held back most by balance-sheet weakness (negative equity) and recent bearish technical momentum; valuation is also demanding with a ~32.8 P/E and no dividend.

To see Spark’s full report on INDV stock, click here.

More about Indivior

Indivior Pharmaceuticals, Inc., listed on Nasdaq as INDV, is a specialty pharmaceuticals company focused on treatments for opioid use disorder. Its flagship product is SUBLOCADE, a long-acting injectable for moderate to severe OUD, and the company has a primary commercial focus on the U.S. market, where it is sharpening its operating model and growth agenda.

Average Trading Volume: 2,324,383

Technical Sentiment Signal: Buy

Current Market Cap: $4.13B

For a thorough assessment of INDV stock, go to TipRanks’ Stock Analysis page.